Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Acasti Pharma, Inc. (NASDAQ: ACST).

Full DD Report for ACST

You must become a subscriber to view this report.


Recent News from (NASDAQ: ACST)

Acasti Pharma Retains Crescendo Communications for Investor Relations Services in the United States
LAVAL, Québec, May 18, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (TSX-V:ACST) (the “ Company ” or “ Acasti Pharma ”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate ...
Source: GlobeNewswire
Date: May, 18 2018 07:00
Acasti Pharma Announces Full Exercise of Over-Allotment Option
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. LAVAL, Quebec, May 14, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “ Company ” or “ Acasti ”) is pleased to announce that Mackie Research Capital ...
Source: GlobeNewswire
Date: May, 14 2018 13:23
Acasti Pharma Announces Closing of $10 Million Underwritten Offering
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. LAVAL, Quebec, May 09, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “ Company ” or “ Acasti ”) is pleased to announce that it has closed its previou...
Source: GlobeNewswire
Date: May, 09 2018 12:42
Acasti Pharma Appoints Donald Olds to its Board of Directors and Audit Committee
LAVAL, Québec, April 27, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (TSX-V:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hy...
Source: GlobeNewswire
Date: April, 27 2018 08:00
Acasti Pharma Prices $10 Million Underwritten Offering
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. LAVAL, Quebec, April 24, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “ Company ” or “ Acasti ”) is pleased to announce that, in connection with its...
Source: GlobeNewswire
Date: April, 24 2018 12:17
Acasti Pharma Announces Overnight Marketed Public Unit Offering
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. Laval, QUEBEC, April 23, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “ Company ” or “ Acasti ”) is pleased to announce that it has filed a prelimi...
Source: GlobeNewswire
Date: April, 23 2018 16:10
Acasti Pharma Announces First Patient Randomized in Pivotal TRILOGY Phase 3 Program of CaPre in Severe Hypertriglyceridemia
LAVAL, QUÉBEC--(Marketwired - March 14, 2018) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST) today announced that the first patient has been randomized in the company's TRILOGY Phase 3 program evaluating lead drug candidate CaPre® (omega-3 phospholipid) for the treatment of...
Source: Marketwired
Date: March, 14 2018 08:00
Acasti Pharma Reports Third Quarter FY 2018 Financial Results
LAVAL, QUÉBEC--(Marketwired - Feb. 13, 2018) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe...
Source: Marketwired
Date: February, 13 2018 17:00
Acasti Pharma Announces the Closing of Over-Allotment Option for its Public Offering of Common Shares
LAVAL, QUÉBEC--(Marketwired - Jan. 22, 2018) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe...
Source: Marketwired
Date: January, 22 2018 17:05
Acasti Pharma Announces Change to Board of Directors
LAVAL, QUÉBEC--(Marketwired - Jan. 16, 2018) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe...
Source: Marketwired
Date: January, 16 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-170.45190.456110.4650.4501120,711
2018-08-160.460.4580.460.4342144,889
2018-08-150.45010.4550.460.440153,182
2018-08-140.440.44210.46940.44289,740
2018-08-130.49360.46020.50290.4333357,752

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-177,05530,64223.0240Cover
2018-08-1611,60148,72123.8111Cover
2018-08-151910,1060.1880Cover
2018-08-1476,302172,13344.3274Short
2018-08-1323,54089,04926.4349Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ACST.


About Acasti Pharma, Inc. (NASDAQ: ACST)

Logo for Acasti Pharma, Inc. (NASDAQ: ACST)

Not available

 

Contact Information

 

 

Current Management

  • Henri Harland / CEO, President
  • Andre Godin / CFO

Current Share Structure

  • Market Cap: $10,979,839 - 03/20/2018
  • Issue and Outstanding: 10,712,038 - 02/29/2016

 


Recent Filings from (NASDAQ: ACST)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 14 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 09 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 09 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 24 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 24 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 24 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 24 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 02 2018

 

 


Daily Technical Chart for (NASDAQ: ACST)

Daily Technical Chart for (NASDAQ: ACST)


Stay tuned for daily updates and more on (NASDAQ: ACST)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ACST)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ACST is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ACST and does not buy, sell, or trade any shares of ACST. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/